Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ARS Pharmaceuticals
Pharma
ARS inks ex-US licensing pact for Neffy worth up to $465M
ARS will receive up to $465 million in a new licensing pact with ALK-Abelló to sell its epinephrine nasal spray Neffy in certain ex-U.S. territories.
Fraiser Kansteiner
Nov 11, 2024 9:44am
ARS has 'blue sky opportunity' in launching neffy, analyst says
Aug 21, 2024 12:48pm
ARS hits major setback in bid to launch epinephrine newcomer
Sep 20, 2023 10:31am
FDA accepts ARS' filing for nasal spray EpiPen rival for review
Oct 25, 2022 10:27am
ARS inks reverse merger to get epinephrine nasal spray to market
Jul 26, 2022 10:22am
Meet Neffy, the kid-friendly epinephrine nasal spray from ARS
Sep 3, 2021 11:27am
